Completed PHASE4 INTERVENTIONAL 2-arm NCT00537771

Liver Safety Under Upfront Arimidex vs Tamoxifen (HEART)

A Prospective, Randomized, Multicentre, Comparative and Open-label Study on Hepatotoxicity of ARIMIDEX Compared With Tamoxifen in Adjuvant Therapy in Postmenopausal Women With Hormone Receptor+ Early Breast Cancer

Sponsor: AstraZeneca

Conditions Breast Cancer

Interventions Anastrozole Tamoxifen

Updated 6 times since 2017 Last updated: Dec 20, 2012 Started: Sep 30, 2007 Primary completion: Dec 31, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Breast Cancer and is currently completed. AstraZeneca leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Changchun, China , Chengdu, China , Dalian, China , Fuzhou, China , Guangzhou, China , Hangzhou, China , Jinan, China , Kunming, China , Nanjing, China , Nanning, China and 6 more locations